W
Won-Shik Choi
Researcher at University of Alberta
Publications - 8
Citations - 175
Won-Shik Choi is an academic researcher from University of Alberta. The author has contributed to research in topics: Cancer cell & Mitotic catastrophe. The author has an hindex of 4, co-authored 7 publications receiving 83 citations. Previous affiliations of Won-Shik Choi include Cross Cancer Institute.
Papers
More filters
Journal ArticleDOI
Prolonged mitotic arrest induced by Wee1 inhibition sensitizes breast cancer cells to paclitaxel.
Cody W. Lewis,Zhigang Jin,Zhigang Jin,Dawn Macdonald,Dawn Macdonald,Wenya Wei,Xu Jing Qian,Won-Shik Choi,Ruicen He,Xuejun Sun,Xuejun Sun,Gordon K. Chan,Gordon K. Chan +12 more
TL;DR: This study shows premature mitotic cells that arise from MK-1775 treatment exhibited centromere fragmentation, a morphological feature of mitotic catastrophe that is characterized by centromeres and kinetochore proteins that co-cluster away from the condensed chromosomes and finds that paclitaxel enhances MK- 1775 mediated cell killing in breast cancer cells.
Journal ArticleDOI
Upregulation of Myt1 Promotes Acquired Resistance of Cancer Cells to Wee1 Inhibition.
Cody W. Lewis,Cody W. Lewis,Amirali B. Bukhari,Amirali B. Bukhari,Edric J. Xiao,Won-Shik Choi,Won-Shik Choi,Joanne D. Smith,Joanne D. Smith,Ellen Homola,John R. Mackey,John R. Mackey,Shelagh D. Campbell,Armin M. Gamper,Armin M. Gamper,Gordon K. Chan,Gordon K. Chan +16 more
TL;DR: It is demonstrated that upregulating Myt1 is a mechanism by which cancer cells acquire resistance to Adavosertib, and downregulating myt1 enhanced ectopic Cdk1 activity and restored sensitivity to Advosert ib.
Journal ArticleDOI
NFIB promotes cell survival by directly suppressing p21 transcription in TP53‐mutated triple‐negative breast cancer
Rong-Zong Liu,Saket Jain,Won-Shik Choi,Elizabeth Garcia,Elizabeth A. Monckton,John R. Mackey,Roseline Godbout +6 more
TL;DR: The results indicate that NFIB is an important TNBC factor that drives tumour cell growth and drug resistance, leading to poor clinical outcomes, and targeting NFIB in TP53‐mutated TNBC may reverse oncogenic properties associated with mutant p53 by restoring p21 activity.
Journal ArticleDOI
Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma
Hamid Maadi,Mohammad Hasan Soheilifar,Won-Shik Choi,Abdolvahab Moshtaghian,Abdolvahab Moshtaghian,Zhixiang Wang +5 more
TL;DR: A review of the various mechanisms of action of trastuzumab for HER2-targeted breast cancer patients can be found in this article, where the authors aimed to provide a detailed insight into the various mechanism of action.
Journal ArticleDOI
The FABP12/PPARγ pathway promotes metastatic transformation by inducing epithelial-to-mesenchymal transition and lipid-derived energy production in prostate cancer cells.
Rong-Zong Liu,Won-Shik Choi,Saket Jain,Deepak Dinakaran,Xia Xu,Woo Hyun Han,Xiao‐Hong Yang,Darryl D. Glubrecht,Ronald B. Moore,Hélène Lemieux,Roseline Godbout +10 more
TL;DR: A novel role is pointed to for a FABP‐PPAR pathway in promoting PCa metastasis through induction of EMT and lipid bioenergetics and increased reliance on fatty acids for energy production.